MHRA limits retigabine indications

on the 1 August 2013

The MHRA has limited the use of the adjunctive anti-epileptic treatment retigabine (Trobalt) to patients with partial onset seizures with or without secondary generalisation where other appropriate drug combinations have proved inadequate or have not been tolerated.

The ophthalmic examination required when prescribing retigabine (Trobalt) should include a visual acuity test, dilated fundoscopy and a slit -lamp examination (pictured) | SCIENCE PHOTO LIBRARY
The ophthalmic examination required when prescribing retigabine (Trobalt) should include a visual acuity test, dilated fundoscopy and a slit -lamp examination (pictured) | SCIENCE PHOTO LIBRARY

The decision to restrict retigabine (Trobalt) was based on reports of adverse effects in long-term studies, including pigmentation of the skin, nails, lips and ocular tissues (including the retina).

Warn patient and perform eye examination before starting

When initiating therapy, healthcare professionals should inform patients of the risk of pigmentation with long-term treatment and perform a comprehensive ophthalmological examination before starting treatment and at least every 6 months thereafter.

Patients currently receiving retigabine should be identified and reviewed at a routine appointment. In addition, they should have an appointment scheduled for an ophthalmic examination.

MHRA Drug Safety Update July 2013

View Trobalt drug record

Further information: GlaxoSmithKline

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Twitter  

More from MIMS

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

Cases of necrotising fasciitis of the genitalia or...

New advice for carbimazole over malformation and pancreatitis risks

New advice for carbimazole over malformation and pancreatitis risks

Reports of congenital malformations and acute pancreatitis...

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Antibiotic Treatments in Adults, Summary of Regimens

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.